BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21965338)

  • 1. Insight into the heterogeneity of breast cancer through next-generation sequencing.
    Russnes HG; Navin N; Hicks J; Borresen-Dale AL
    J Clin Invest; 2011 Oct; 121(10):3810-8. PubMed ID: 21965338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
    Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
    Elife; 2020 May; 9():. PubMed ID: 32401198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new genome-driven integrated classification of breast cancer and its implications.
    Dawson SJ; Rueda OM; Aparicio S; Caldas C
    EMBO J; 2013 Mar; 32(5):617-28. PubMed ID: 23395906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical target sequencing for precision medicine of breast cancer.
    Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
    Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The breast cancer genome--a key for better oncology.
    Vollan HK; Caldas C
    BMC Cancer; 2011 Nov; 11():501. PubMed ID: 22128823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Sequencing-Based Biomarkers in Breast Cancer.
    Han W; Lim W
    Adv Exp Med Biol; 2021; 1187():323-335. PubMed ID: 33983586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer.
    Kim RN; Moon HG; Han W; Noh DY
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29414922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic heterogeneity in breast cancer: the road to personalized medicine?
    Baird RD; Caldas C
    BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
    De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
    Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
    Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
    Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Pathology and Biomarkers in Breast Cancer.
    Zhang Z; Tang P
    Crit Rev Oncog; 2017; 22(5-6):411-426. PubMed ID: 29604921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing in the clinic: promises and challenges.
    Xuan J; Yu Y; Qing T; Guo L; Shi L
    Cancer Lett; 2013 Nov; 340(2):284-95. PubMed ID: 23174106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoral heterogeneity of breast cancer.
    Roulot A; Héquet D; Guinebretière JM; Vincent-Salomon A; Lerebours F; Dubot C; Rouzier R
    Ann Biol Clin (Paris); 2016 Dec; 74(6):653-660. PubMed ID: 27848916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
    Stover DG; Wagle N
    Curr Oncol Rep; 2015 Apr; 17(4):15. PubMed ID: 25708799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumor Heterogeneity in Breast Cancer.
    Beca F; Polyak K
    Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation analysis of breast cancer genomes for precision medicine.
    Previati M; Manfrini M; Galasso M; Zerbinati C; Palatini J; Gasparini P; Volinia S
    Cancer Lett; 2013 Oct; 339(1):1-7. PubMed ID: 23879964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.